Management of Newly Diagnosed Myeloma

S Vincent Rajkumar, Antonio Palumbo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.

Original languageEnglish (US)
Pages (from-to)1141-1156
Number of pages16
JournalHematology/Oncology Clinics of North America
Volume21
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Thalidomide
Melphalan
Stem Cell Transplantation
Prednisone
Dexamethasone
Standard of Care
Multiple Myeloma
Therapeutics
lenalidomide
Bortezomib

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Management of Newly Diagnosed Myeloma. / Rajkumar, S Vincent; Palumbo, Antonio.

In: Hematology/Oncology Clinics of North America, Vol. 21, No. 6, 12.2007, p. 1141-1156.

Research output: Contribution to journalArticle

Rajkumar, S Vincent ; Palumbo, Antonio. / Management of Newly Diagnosed Myeloma. In: Hematology/Oncology Clinics of North America. 2007 ; Vol. 21, No. 6. pp. 1141-1156.
@article{5ec6d27e610b4d9890fd377135a8993d,
title = "Management of Newly Diagnosed Myeloma",
abstract = "The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.",
author = "Rajkumar, {S Vincent} and Antonio Palumbo",
year = "2007",
month = "12",
doi = "10.1016/j.hoc.2007.08.008",
language = "English (US)",
volume = "21",
pages = "1141--1156",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Management of Newly Diagnosed Myeloma

AU - Rajkumar, S Vincent

AU - Palumbo, Antonio

PY - 2007/12

Y1 - 2007/12

N2 - The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.

AB - The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.

UR - http://www.scopus.com/inward/record.url?scp=35748974554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748974554&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2007.08.008

DO - 10.1016/j.hoc.2007.08.008

M3 - Article

C2 - 17996592

AN - SCOPUS:35748974554

VL - 21

SP - 1141

EP - 1156

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -